How Much Is Wegovy Compared to Mounjaro? UK Private Costs Explained

What UK clinical trials showed, and why it matters when you compare prices

The two medicines are not identical in how they work, which affects how clinicians think about value. Mounjaro (tirzepatide) activates two gut-hormone receptors (GIP and GLP-1) while Wegovy (semaglutide) acts on GLP-1 alone. In the SURMOUNT-1 trial, tirzepatide produced an average body-weight reduction of around 20–21% at the highest dose over 72 weeks, as published in the New England Journal of Medicine. Wegovy at 2.4mg delivered roughly 15% in the STEP 1 trial. The 2025 SURMOUNT-5 head-to-head confirmed tirzepatide's greater average loss compared with semaglutide 2.4mg.

That said, Wegovy's ceiling has moved. Novo Nordisk's 7.2mg dose (approved by the MHRA in April 2026) reported around 20.7% average weight loss over 72 weeks, closing the gap with Mounjaro's top dose considerably. NICE's appraisal of tirzepatide (TA1026) notes that indirect comparisons favour tirzepatide, but acknowledges the evidence base continues to develop. Neither trial result guarantees any individual outcome; what a person actually loses depends on dose, duration, adherence and clinical factors their prescriber reviews.

Knowing this context matters for a price comparison. If you want to dig into how the two medicines sit against each other on cost, our page on how Wegovy price compares to Mounjaro is a useful starting point before drawing any conclusions. If Mounjaro is priced higher at a given dose than Wegovy at an equivalent dose, you are partly paying for a different mechanism, not simply a premium for the same thing.

How UK private pricing actually works for these two medicines

Since Eli Lilly increased Mounjaro's UK list price on 1 September 2025 (with the highest-dose pen rising from roughly £122 to around £330 at list) private providers have repriced accordingly. As widely reported, typical private monthly costs now sit somewhere between £149 and £375, varying by dose and provider, for both medicines. Lower doses cost less; maintenance doses cost more. That is the honest market picture, hedged as it should be: prices shift, and no two providers publish identical structures.

For a genuinely useful comparison, you need to look at what a monthly figure includes, not just the number. Our cost breakdown for Wegovy versus Mounjaro goes through this in more detail. At a headline level: some providers charge separately for consultation, for the prescription itself, and for delivery, three line items that can quietly add £30–£70 or more to a low-looking monthly figure. Others bundle differently. A price that looks cheaper by £20 on a comparison site may cost the same or more once everything is added up.

If you want a structured side-by-side of what each medicine costs across doses and providers, our Mounjaro and Wegovy price comparison lays that out clearly so you can see where the differences actually fall. There is also a dose question. If you want to understand how the doses sit relative to each other before comparing costs, our page on what 5mg of Mounjaro equates to in Wegovy terms is worth reading first.

What one transparent price actually means, and where we stand

At nume, a single quoted price covers the clinical consultation, the prescription, the medicine and next-working-day DPD delivery. Seven-day aftercare is included. There is no subscription, and every repeat order is reviewed clinically before anything is dispatched. If you order by midday on a working day and your prescriber approves your consultation, your pen leaves our GPhC-registered pharmacy the same afternoon.

We are not the cheapest option, and we are not trying to be. What that buys you is a real prescriber (a named, GPhC-registered Independent Prescriber) reading your consultation the day you submit it, not an algorithm flagging it for a later batch review. Our clinical team makes that call. Current treatment pricing is shown on our weight-loss treatments page.

It is also worth noting that neither Wegovy nor Mounjaro is available through a legitimate online pharmacy without a clinical assessment, this is UK law, not a policy choice. Anyone offering either medicine at a conspicuously low price, without a documented prescribing process, is a red flag. The MHRA seized roughly 20 million doses of illegally traded weight-loss medicines (around £45m street value) in 2025 alone, and has warned publicly about counterfeit pens that have contained insulin rather than the labelled medicine. You can verify any online pharmacy on the GPhC register before you buy.

Which medicine is better value? The clinical answer

A question our prescribers hear regularly is whether Mounjaro's typically higher price is justified compared with Wegovy. The clinical honest answer is: it depends on the individual. Mounjaro's dual-receptor action and SURMOUNT-1 results make it the stronger medicine on average in trial populations. But some people do exceptionally well on semaglutide; others find one medicine's side-effect profile easier to tolerate than the other's. Cost matters, but so does tolerability, your medical history, and what dose is clinically appropriate for you, none of which a price table can settle.

For a side-by-side on how the two medicines compare beyond cost, our Wegovy versus Mounjaro overview covers the clinical picture. If the semaglutide content of Mounjaro is something you want to understand (it has none; tirzepatide is a different molecule) our page on semaglutide in Mounjaro clears that up. Price is a legitimate part of the decision. It just should not be the only part. Speak to our prescribers to work out which medicine suits your situation, at a price that includes everything you actually need.